Assenagon Asset Management S.A. increased its position in REGENXBIO Inc. (NASDAQ: RGNX) by 23.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 705,403 shares of the biotechnology company's stock after purchasing an additional 132,942 shares during the
REGENXBIO Inc. (NASDAQ: RGNX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the
ROCKVILLE, Md. , Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P.
ROCKVILLE, Md. , Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference: Piper Sandler 37th Annual Healthcare Conference Fireside Chat: Tuesday, December 2 at 8:30 a.m.
REGENXBIO Inc. ( RGNX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Patrick Christmas - Executive VP & Chief Strategy and Legal Officer Curran Simpson - President, CEO & Director Steve Pakola - Executive VP & Chief Medical Officer Mitchell Chan - Executive VP & CFO Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Lili Nsongo - Leerink Partners LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Luca Issi - RBC Capital Markets, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Alec Stranahan - BofA Securities, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Sean McCutcheon - CGS International Daniil Gataulin - Chardan Capital Markets, LLC, Research Division Bill Man Yi Chen - H.C.
Regenxbio (RGNX) came out with a quarterly loss of $1.2 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to a loss of $1.17 per share a year ago.
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed in October; confirmatory trial open and enrolling New 12-month analysis shows all participants demonstrate improved functional outcomes across multiple natural history methods of measurement, when decline is expected Clemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026 Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy for chronic retinal disease Enrollment completed in pivotal trials evaluating subretinal delivery of sura-vec in wet AMD; topline data expected Q4 2026 Sura-vec for diabetic retinopathy using suprachoroidal delivery advancing to global pivotal program, supported by positive 2-year Phase II trial data Conference call today at 8:00 a.m. ET ROCKVILLE, Md.
Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO Inc. (NASDAQ: RGNX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 176,999 shares of the biotechnology company's stock, valued at approximately $1,453,000. Y Intercept Hong
Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II portion of AFFINITY DUCHENNE® trial supporting potential approval via the accelerated approval pathway REGENXBIO continues to enroll patients in the confirmatory trial First batches intended for commercial supply manufactured at in-house Manufacturing Innovation Center Capacity to produce up to 2,500 RGX-202 doses per year Topline pivotal data now expected in early Q2 2026 and BLA submission in mid-2026 ROCKVILLE, Md. , Oct. 30, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the completion of enrollment in the AFFINITY DUCHENNE® pivotal trial of RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy, as well as the successful production of the first batches intended for commercial supply.
ROCKVILLE, Md. , Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m.
